View in EDS

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Saved in:
Bibliographic Details
Title: Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Authors: Carter, C. A.1, Rajan, A.2, Keen, C.2, Szabo, E.3, Khozin, S.2, Thomas, A.2, Brzezniak, C.1, Guha, U.2, Doyle, L. A.4, Steinberg, S. M.5, Xi, L.6, Raffeld, M.6, Tomita, Y.2, Lee, M. J.2, Lee, S.2, Trepel, J. B.2, Reckamp, K. L.7, Koehler, S.7, Gitlitz, B.8, Salgia, R.9
Source: Annals of Oncology. Apr2016, Vol. 27 Issue 4, p693-699. 7p. 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first